Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160716 · ClinicalTrials.gov registry record · NA
Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
A NA study of Cheek Augmentation and Midface Contour Deficiencies, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT03160716 is a NA study of Cheek Augmentation and Midface Contour Deficiencies that has completed, run by Galderma R&D. The registered enrollment target is 60 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT03160716, a NA study of Cheek Augmentation and Midface Contour Deficiencies, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multi-center, open-label, single-arm study to evaluate an injection tool with Restylane Lyft with Lidocaine for cheek augmentation and correction of age related midface contour deficiencies.
Conditions Studied
Interventions
- DEVICE Restylane Lyft with Lidocaine
Study Locations (4)
California
- Facial Plastic and Cosmetic Surgery - Beverly Hills
- Skin Care and Laser Physicians of Beverly Hills - Los Angeles
- Hessler Plastic Surgery - Palo Alto
New York
- Union Square Laser Dermatology - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2017-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160716
The ClinicalTrials.gov registry entry for NCT03160716 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cheek Augmentation appearing as the primary indexed condition, and to 1 intervention - of which Restylane Lyft with Lidocaine is the first listed.
NCT03160716 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT03160716 about?
NCT03160716 is a clinical study titled "Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation". This is a multi-center, open-label, single-arm study to evaluate an injection tool with Restylane Lyft with Lidocaine for cheek augmentation and correction of age related midface contour deficiencies.
What is the current status of trial NCT03160716?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-05-16. Estimated completion is 2017-10-31.
What conditions does trial NCT03160716 study?
This clinical trial studies the following conditions: Cheek Augmentation, Midface Contour Deficiencies.
What interventions are being tested in trial NCT03160716?
The interventions under investigation include: Restylane Lyft with Lidocaine (DEVICE).
Who is sponsoring clinical trial NCT03160716?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03160716 being conducted?
This trial has 4 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.